

Overland Pharmaceuticals Appoints Dr. Xun Liu as Chief Technology Officer

03 March 2022 | News

Dr. Liu will be responsible for overseeing the company's global technical operations including chemistry, manufacturing, and controls (CMC) of product development and commercialization.



Overland Pharmaceuticals, a premier biopharmaceutical company bringing innovative medicines to patients in Asia and worldwide, has announced the appointment of Dr. Xun Liu, as Chief Technology Officer (CTO). In this new role, Dr. Liu will be responsible for overseeing the company's global technical operations including chemistry, manufacturing, and controls (CMC) of product development and commercialization.

Dr. Liu will continue serving in his role as Senior Advisor at Hillhouse Investment, a position he has held to date. Prior to joining Hillhouse Investment, Dr. Liu was the Vice President of Hengrui Medicine and the President of its Biomedicine Development and Business Division where he oversaw the development of over 50 new biological products, 23 of which entered clinical trials and 3 were approved for market launch. Previously, Dr. Liu was a tenured Staff Scientist at the Vaccine Research Center of the National Institutes of Health (NIH), where he was in charge of process development and clinical manufacturing of therapeutic and prophylactic vaccines. Prior to his role at the NIH, he was the Principal Engineer at Bayer HealthCare Pharmaceuticals, serving as Commercial Production Specialist for Kogenate®, Bayer's top selling drug. Earlier in his career, he worked at Amgen and Vertex Pharmaceuticals in various drug development roles.

Dr. Liu earned a Bachelor of Science degree in chemistry from Beijing University and Ph.D. degree in biophysical chemistry from Rutgers University. Following his education, he was trained at Massachusetts Institute of Technology (MIT) as a post-doc fellow in the Nobel Laureate Professor Gobind Khorana's laboratory for three and a half years.